Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||LAG525 + MCS110 + Spartalizumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|LAG525||Immune Checkpoint Inhibitor 94 LAG3 Antibody 10||LAG525 is a monoclonal antibody that targets LAG3 and blocks interaction with MHC class II molecules, leading to enhanced T-cell response to tumor cells and decreased tumor growth (NCI Drug Dictionary).|
|MCS110||CSF1 Antibody 2||MCS110 is a monoclonal antibody that binds CSF1 and prevents receptor binding and subsequent receptor activation, and leads to reduction of tumor-related bone destruction (Cancer Res; 2009 Apr 18-22; Abstract nr DDT02-2).|
|Spartalizumab||PDR001|PDR-001||Immune Checkpoint Inhibitor 94 PD-L1/PD-1 antibody 63||Spartalizumab (PDR001) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 32364844, PMID: 32179633).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03742349||Phase I||Canakinumab + LAG525 + Spartalizumab LAG525 + MCS110 + Spartalizumab Capmatinib + LAG525 + Spartalizumab LAG525 + PBF-509 + Spartalizumab||Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).||Recruiting|